Evidence map›Paper›PMID 32622332›Full record

ArticleMolecular therapy. Nucleic acids2020

Functional Significance and Therapeutic Potential of miRNA-20b-5p in Esophageal Squamous Cell Carcinoma.

Jiarui Yu, Siyuan Chen, Yi Niu, Meiyue Liu, Jie Zhang, Zhao Yang, Peng Gao, Wei Wang, Xiaochen Han, Guogui Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. miRNA in head and neck squamous cell carcinomas: promising but still distant future of personalized oncology.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jiarui YuSchool of Clinical Medicine, Affiliated Hospital, School of Public Health, North China University of Science and Technology, Tangshan, Hebei 063210, China; Department of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China.
Siyuan ChenDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China.
Yi NiuDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China.
Meiyue LiuSchool of Clinical Medicine, Affiliated Hospital, School of Public Health, North China University of Science and Technology, Tangshan, Hebei 063210, China; Department of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China.
Jie ZhangDepartment of pathology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China.
Zhao YangDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China.
Peng GaoDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China.
Wei WangDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China.
Xiaochen HanDepartment of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China. Electronic address: 18931521050@163.com.
Guogui SunSchool of Clinical Medicine, Affiliated Hospital, School of Public Health, North China University of Science and Technology, Tangshan, Hebei 063210, China; Department of Radiation Oncology, North China University of Science and Technology Affiliated People's Hospital, Tangshan 063000, China. Electronic address: guogui_sun2013@163.com.
North China University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel therapies tailored to the molecular composition mechanism of esophageal squamous cell carcinoma (ESCC) are needed to improve patient survival. miR-20b-5p expression was significantly upregulated in cancerous tissues and associated with lymph node metastasis, clinical stage, and overall survival (OS). An analysis of the methylation status of the miR-20b-5p gene indicated that the hypomethylation of the CpG sites located upstream of the miR-20b-5p gene in the ESCC tissues was more frequent than in the adjacent normal tissues, and the methylation status of miR-20b-5p correlated inversely with its expression levels. Notably, a series of gain- and loss-of-function assays elucidated that miR-20b-5p promoted ESCC cell proliferation, migration, and invasion both in vitro and in vivo. Luciferase reporter assays, western blot, and qRT-PCR revealed that RB1 and TP53INP1 were the direct targets of miR-20b-5p. Moreover, the effects of ectopic miR-20b-5p expression were abrogated by RB1 and TP53INP1 overexpression. In contrast, the effects of miR-20b-5p depletion were impaired by RB1 and TP53INP1 knockdown. Treatment with a miR-20b-5p antagomir dramatically increased tumor growth and inhibited RB1 and TP53INP1 protein expression in nude mice. This work provided novel insights on the molecular mechanism of ESCC and further provided suggestions for therapy development.

Indexed as

biomarkersESCCesophageal squamous cell carcinomamethylationmicroRNAs

Identifiers

PMID32622332
PMCPMC7334444
OpenAlexW3038420150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.